Literature DB >> 27118008

[Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].

V J J Schettler1, J Ringel2, S Jacob3, U Julius4, R Klingel5, F Heigl6, E Roeseler7, P Grützmacher8.   

Abstract

Entities:  

Keywords:  Apheresis, lipoproteins; Cardiovascular diseases; Cholesterol, LDL; Guideline; PCSK9-Inhibitors

Mesh：

Substances：

Year:  2016        PMID： 27118008     DOI： 10.1007/s00108-016-0043-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  33 in total

Review 1.  Lipid lowering with PCSK9 inhibitors.

Authors:  Razvan T Dadu; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

2.  First data from the German Lipoprotein Apheresis Registry (GLAR).

Authors:  Volker J J Schettler; Class L Neumann; Christian Peter; Thomas Zimmermann; Ulrich Julius; Eberhard Roeseler; Franz Heigl; Wolfgang Ramlow; Helmut Blume
Journal:  Atheroscler Suppl       Date:  2015-05       Impact factor: 3.235

Review 3.  Lipoprotein apheresis--more than just cholesterol reduction?

Authors:  Claas L Neumann; Egbert G Schulz; Gerit C Hagenah; Ulf Platzer; E Wieland; Volker Schettler
Journal:  Atheroscler Suppl       Date:  2013-01       Impact factor: 3.235

4.  Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment.

Authors:  Klaus P Mellwig; Frank van Buuren; Henning K Schmidt; Peter Wielepp; Wolfgang Burchert; Dieter Horstkotte
Journal:  Ther Apher Dial       Date:  2006-12       Impact factor: 1.762

Review 5.  Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.

Authors:  C Michael White
Journal:  Ann Pharmacother       Date:  2015-09-30       Impact factor: 3.154

6.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Authors:  Jordan Fulcher; Rachel O'Connell; Merryn Voysey; Jonathan Emberson; Lisa Blackwell; Borislava Mihaylova; John Simes; Rory Collins; Adrienne Kirby; Helen Colhoun; Eugene Braunwald; John La Rosa; T R Pedersen; Andrew Tonkin; Barry Davis; Peter Sleight; Maria Grazia Franzosi; Colin Baigent; Anthony Keech
Journal:  Lancet       Date:  2015-01-09       Impact factor: 79.321

7.  Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Authors:  Erin A Bohula; Robert P Giugliano; Christopher P Cannon; Jing Zhou; Sabina A Murphy; Jennifer A White; Andrew M Tershakovec; Michael A Blazing; Eugene Braunwald
Journal:  Circulation       Date:  2015-09-01       Impact factor: 29.690

8.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

Authors:  H Mabuchi; J Koizumi; M Shimizu; K Kajinami; S Miyamoto; K Ueda; T Takegoshi
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

9.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

10.  Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.

Authors:  Volker J J Schettler; Class L Neumann; Christian Peter; Thomas Zimmermann; Ulrich Julius; Eberhard Roeseler; Franz Heigl
Journal:  Clin Res Cardiol Suppl       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.